Non–Vitamin K Antagonist Oral Anticoagulants effective in Stroke treatment
Stroke management is very crucial as as neurons do not survive longer in case of hypoxia. Current guidelines recommend against use of intravenous alteplase in patients with acute ischemic stroke who are taking non–vitamin K antagonist oral anticoagulants (NOACs).
A recent Results published in JAMA Network concluded that Among patients with acute ischemic stroke treated with intravenous alteplase, use of non–vitamin K antagonist oral anticoagulants within the preceding 7 days was not associated with a significantly increased risk of intracranial hemorrhage.
Study evaluated the safety and functional outcomes of intravenous alteplase among patients who were taking non–vitamin K antagonist oral anticoagulants prior to stroke and compared the outcomes with patients who were not taking long-term anticoagulants.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.